European Society of Intensive Care Medicine Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2002
NCT00147004
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

European Society of Intensive Care Medicine

Active Ingredients

Drugs in Phase 3 Trials (1)

urea (1 trial)

Drugs in Other Trials (4)

arginine (1 trial)

lactic acid (1 trial)

vitamin c (1 trial)

zinc sulfate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Shock (Phase 3)

Shock, Septic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5